1. Volume 62, Issue 3, Pages 472-487 (September 2012)
Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis 
Alberto Briganti, Thomas Wiegel, Steven Joniau, Cesare Cozzarini, Marco Bianchi, Maxine Sun, Bertrand Tombal, Karin Haustermans, Tom Budiharto, Wolfgang Hinkelbein, Nadia Di Muzio, Pierre I. Karakiewicz, Francesco Montorsi, Hein Van Poppel 
European Urology 
Volume 62, Issue 3, Pages (September 2012)
DOI: /j.eururo
Copyright © 2012 European Association of Urology Terms and Conditions

2. Fig. 1
Temporal trends in adjuvant radiation therapy (aRT) versus initial observation (obs) and eventual early salvage radiation therapy (eSRT) use (A) within the overall prematch patient population; (B) after propensity score matching, when eSRT was defined as radiation therapy administered at a prostate-specific antigen (PSA) ≤0.5 ng/ml; and (C) after propensity score matching, when eSRT was defined as radiation therapy administered at a PSA ≤0.3 ng/ml.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.5 ng/ml) in cases of relapse (n=390 given for the two arms separately; log-rank test: p=0.9; hazard ratio: 0.9).
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

4. Fig. 3
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤ 0.5 ng/ml) in cases of relapse in patients with (A) pT3a disease, (B) pT3b disease, (C) negative surgical margins, or (D) positive surgical margins.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

5. Fig. 3
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤ 0.5 ng/ml) in cases of relapse in patients with (A) pT3a disease, (B) pT3b disease, (C) negative surgical margins, or (D) positive surgical margins.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

6. Fig. 4
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.5 ng/ml) in cases of relapse in patients with (A) pT3a disease and negative surgical margins (NSM), (B) pT3a disease and positive surgical margins, and (C) pT3b disease and NSM.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

7. Fig. 4
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.5 ng/ml) in cases of relapse in patients with (A) pT3a disease and negative surgical margins (NSM), (B) pT3a disease and positive surgical margins, and (C) pT3b disease and NSM.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

8. Fig. 5
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.3 ng/ml) in cases of relapse (n=390 given for the two arms separately; log-rank test: p=0.7; hazard ratio: 0.8).
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

9. Fig. 6
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.3 ng/ml) in cases of relapse in patients with (A) pT3a disease, (B) pT3b disease, (C) negative surgical margins, or (D) positive surgical margins.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

10. Fig. 6
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.3 ng/ml) in cases of relapse in patients with (A) pT3a disease, (B) pT3b disease, (C) negative surgical margins, or (D) positive surgical margins.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

11. Fig. 7
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.3 ng/ml) in cases of relapse in patients with (A) pT3a disease and negative surgical margins (NSM), (B) pT3a disease and positive surgical margins, and (C) pT3b disease and NSM.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

12. Fig. 7
Kaplan-Meier estimates of biochemical recurrence–free survival in patients receiving adjuvant radiation therapy (aRT) versus observation (obs) and early salvage radiation therapy (eSRT; prostate-specific antigen at salvage radiation therapy ≤0.3 ng/ml) in cases of relapse in patients with (A) pT3a disease and negative surgical margins (NSM), (B) pT3a disease and positive surgical margins, and (C) pT3b disease and NSM.
BCR=biochemical recurrence.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions